-
-
NCT01051531
-
Primary Citation
Not Available
-
Data Specification
Not Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NamePaliperidone palmitateProduct NameINVEGA SUSTENNA®Therapeutic AreaBehaviors and Mental DisordersEnrollment546% Female34.5%% White6%
Product ClassAtypical AntipsychoticsSponsor Protocol NumberR092670SCH3009Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)27
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
Approved Data Requests Associated with this Trial
- 2024-0556 : Heterogeneity of treatment effects during guaranteed antipsychotic maintenance treatment in schizophrenia as a window into the mechanisms of treatment
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
- 2021-4667 : Estimation of Geographic and Demographic Variabilities Associated with Schizophrenia Age of Onset and Duration of Untreated Psychosis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment